ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Addex Therapeutics Ltd

Addex Therapeutics Ltd (0QNV)

3.02
0.00
(0.00%)
Closed 22 December 3:30AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
3.02
Bid
0.00
Offer
0.00
Volume
0.00
0.00 Day's Range 0.00
3.02 52 Week Range 3.02
Market Cap
Previous Close
3.02
Open
-
Last Trade
(O)
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
574
Shares Outstanding
184,354,000
Dividend Yield
-
PE Ratio
-52.71
Earnings Per Share (EPS)
-0.06
Revenue
1.61M
Net Profit
-10.56M

About Addex Therapeutics Ltd

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Geneva, Che
Founded
-
Addex Therapeutics Ltd is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0QNV. The last closing price for Addex Therapeutics was CHF3.02. Over the last year, Addex Therapeutics shares have traded in a share price range of CHF 3.02 to CHF 3.02.

Addex Therapeutics currently has 184,354,000 shares in issue. The market capitalisation of Addex Therapeutics is CHF556.75 million. Addex Therapeutics has a price to earnings ratio (PE ratio) of -52.71.

0QNV Latest News

Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND...

Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024

Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024 Nine-month Results Remain On Track for Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva...

Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update

Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM...

Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit

Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex...

Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage...

Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration

Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 27, 2024...

Addex’s Partner Discontinues ADX71149 development in Epilepsy

Addex’s Partner Discontinues ADX71149 development in Epilepsy Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a...

Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)

Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS) Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland...

Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)

Addex To Present at the Thirteenth London International Cough Symposium (13th LICS) Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...

Addex Shareholders Approve All Resolutions at Annual General Meeting

Addex Shareholders Approve All Resolutions at Annual General Meeting Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq:...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1003.023.023.0270003.02DE
4003.023.023.0216673.02DE
12003.023.023.025743.02DE
26003.023.023.028013.02DE
52003.023.023.0215813.02DE
156003.023.023.029493.02DE
260003.023.023.028033.02DE

0QNV - Frequently Asked Questions (FAQ)

What is the current Addex Therapeutics share price?
The current share price of Addex Therapeutics is CHF 3.02
How many Addex Therapeutics shares are in issue?
Addex Therapeutics has 184,354,000 shares in issue
What is the market cap of Addex Therapeutics?
The market capitalisation of Addex Therapeutics is CHF 556.75M
What is the 1 year trading range for Addex Therapeutics share price?
Addex Therapeutics has traded in the range of CHF 3.02 to CHF 3.02 during the past year
What is the PE ratio of Addex Therapeutics?
The price to earnings ratio of Addex Therapeutics is -52.71
What is the cash to sales ratio of Addex Therapeutics?
The cash to sales ratio of Addex Therapeutics is 347.13
What is the reporting currency for Addex Therapeutics?
Addex Therapeutics reports financial results in CHF
What is the latest annual turnover for Addex Therapeutics?
The latest annual turnover of Addex Therapeutics is CHF 1.61M
What is the latest annual profit for Addex Therapeutics?
The latest annual profit of Addex Therapeutics is CHF -10.56M
What is the registered address of Addex Therapeutics?
The registered address for Addex Therapeutics is 12 CHEMIN DES AULX, GENEVA, 1228
What is the Addex Therapeutics website address?
The website address for Addex Therapeutics is www.addextherapeutics.com
Which industry sector does Addex Therapeutics operate in?
Addex Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TIRTiger Royalties And Investments Plc
0.15p
(50.00%)
3.41M
BAYBay Capital Plc
5.50p
(19.57%)
209.68k
MASTMast Energy Developments Plc
0.19p
(18.75%)
20.09M
MHNMenhaden Resource Efficiency Plc
148.50p
(18.33%)
1M
ZENZenith Energy Ltd.
2.50p
(16.28%)
3.93M
TRYBTribe Technology Plc
0.115p
(-79.09%)
24.27M
NMTNeometals Ltd
2.75p
(-35.29%)
49.4k
SNGSynairgen Plc
2.46p
(-34.31%)
4.31M
TM1Technology Minerals Plc
0.185p
(-26.00%)
174.03M
AYMAnglesey Mining Plc
0.70p
(-17.65%)
2.99M
NTVONativo Resources Plc
0.002p
(5.26%)
971.94M
TRPTower Resources Plc
0.035p
(9.38%)
620.03M
LLOYLloyds Banking Group Plc
54.16p
(-0.26%)
341.48M
ORCPOracle Power Plc
0.0255p
(-1.92%)
192.93M
TM1Technology Minerals Plc
0.185p
(-26.00%)
174.03M

Discussion

View Full Feed
joe botts joe botts 27 seconds ago
Holy! Great 6 year old news!
doc2016 doc2016 1 minute ago
now, we seem to have ploinks and puddle on the new msft fabric which seems to incorporate much if not all of vcsy ip with 8 ip?...........anybody think this is what it would be all the time?

now i wonder how this sits with google whose android customers are likely lg, samsung, interwo
getmoreshares getmoreshares 2 minutes ago
Pink Limited Information
NTRR
learningcurve2020 learningcurve2020 2 minutes ago
Here's what pathological lying looks like, btw.  

https://www.breitbart.com/the-media/2024/12/20/nolte-breitbarts-liar-year-2024-award-goes-joe-scarborough/
NWBO
1vman 1vman 3 minutes ago
*****🟥🟥🟥 LOL ! now I am hearing 🟥nonsense🟥Kramer naked shorted DBMM

https://investorshub.advfn.com/uimage/uploads/2024/9/12/ypv[ilaughing-baby.gif

ENOUGH SAID HUZZAH🤪 !!!
DBMM
getmoreshares getmoreshares 3 minutes ago
Held at DTC 2,766,390,658
12/20/2024
DTC
tdbowieknife tdbowieknife 4 minutes ago
Lol... You would only get lies from Klug. The real information is posted here by me.

Right, Could Be 1...

..

.
1vman 1vman 4 minutes ago
***** NO SIR !!! 🚽UBQU🚽 Does not have 5 million in revenues , point in fact financials are not very good and can be found here

https://www.otcmarkets.com/stock/UBQU/disclosure

ENOUGH SAID 🤪 !!!
UBQU
tedpeele tedpeele 4 minutes ago
The answers are staring you all in the face

You can’t see it because you’re stubborn

Some things are too incongruent to ignore. For me the $5.2 million in cash bonuses was one of those things. There are many more, but that was the first thing I saw.

A h
ASM
1vman 1vman 6 minutes ago
*****💩HIRU💩 Historically has been a complete and utter Xpert failure

https://ih.advfn.com/stock-market/USOTC/hiru-pk-HIRU/historical

ENOUGH SAID🤔 !!! HUZZAH🤔 !!!
HIRU
GetSeriousOK GetSeriousOK 6 minutes ago
BIEL BUY RATING based on what?

Barchart uses TA, and TA doesn't work on BIEL because:

The corporation is forfeited in Maryland, its state of incorporation, for the second time in 30 months.

The CEO is the only officer left at this company. All the other o
TREET
DLucky6636 DLucky6636 7 minutes ago
Thx. I hope he moves to Denver. CEO full time remote with COO half time remote is not good for a mature company. For a pre-revenue "startup", it is just not acceptable. If JM wants to semi-retire, I don't blame him. He is at the age and has the money. But just don't hold the COO position. I ho
LWLG
Farmsara Farmsara 8 minutes ago
Spot on, Matt. It’s amazing how some on this board try to spin the December 2023 letter into being something that it wasn’t. No matter how many times I’ve read that letter, no one can convince me that a deal was not going to happen in the short term future based on the CEO’s very own words. Let’s ho
LWLG
learningcurve2020 learningcurve2020 9 minutes ago
Wow, that Advent sure has some operation! 🙄
Nice job pretending to see nothing wrong with it, btw.  
NWBO
TMaga TMaga 9 minutes ago
What was this 9 day meeting all about??? Send in an application for what??? Clinical trials(Can take years) Patent application (Can take up to one year) No guarantees, just a first step.
ADHC
mwab52 mwab52 9 minutes ago
Good morning (RNVA-Land & Team).......🤑😎......Go (RNVA & Team)
RNVA
AlwaysOptimistic AlwaysOptimistic 9 minutes ago
Tiny But Vital Metal Markets Rush to Adjust to Chinese Clampdown

https://finance.yahoo.com/news/tiny-vital-metal-markets-rush-133000810.html
NB
Stock Guy777 Stock Guy777 10 minutes ago
🙄🤦🏻‍♂️
HMBL
doc2016 doc2016 11 minutes ago
goodness, some ploinks and puddle for a monitoring tool and what/how to contain/treat an infestation or hint of one?

for msft teams feds/cisa have new rules...scuba......best practices . binding operational directive for federal civilian agencies...secure cloud business applications.
SkyLimit2022 SkyLimit2022 12 minutes ago
LC,

You raise a valid point about the website: They really should align the main page with the updates from their press releases. ✅️

Thanks for refocusing our attention on the significant developments that have unfolded since the landmark P3 concluded …
NWBO
OPKOHEALTH2022 OPKOHEALTH2022 12 minutes ago
Wethemarket, I found this :
https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title26-section45V&num=0&edition=prelim
FCEL
doc2016 doc2016 12 minutes ago
maybe luiz should work at msft? ibm for the infrastructure and msft for the software.....netvista?
now msft announces microsoft fabric.....sounds like v ip and some 8 magic?
that would be nice.
gemiini responded:
"what is microsoft fabric?


wadegarret wadegarret 12 minutes ago
PSIX extreme volatility is risky

Last quarter, you could buy every dip with confidence, as the stock came back within hours or days every time, and then made new highs. This time the stock just went from $35 to $15, which already is crazy, and now back to $22, which is nowhere near
TMaga TMaga 12 minutes ago
What was the nine day meeting all about? Send in an application for what??? Clinical trials (can take years) Patent application (Can take up to a year) Either is time consuming and doesn't guarantee acceptance. It is just the first step.
ADHC